Reynders McVeigh Capital Management LLC Lowers Stake in Abbott Laboratories $ABT

Reynders McVeigh Capital Management LLC reduced its position in Abbott Laboratories (NYSE:ABT) by 1.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 415,235 shares of the healthcare product maker’s stock after selling 6,426 shares during the quarter. Abbott Laboratories makes up about 1.5% of Reynders McVeigh Capital Management LLC’s investment portfolio, making the stock its 22nd largest holding. Reynders McVeigh Capital Management LLC’s holdings in Abbott Laboratories were worth $37,678,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in ABT. BlackRock Inc. grew its stake in Abbott Laboratories by 4.6% during the second quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock valued at $13,843,610,000 after acquiring an additional 6,769,518 shares in the last quarter. State Street Corp boosted its holdings in shares of Abbott Laboratories by 2.1% in the 4th quarter. State Street Corp now owns 79,853,782 shares of the healthcare product maker’s stock worth $10,004,880,000 after purchasing an additional 1,627,791 shares during the period. Capital International Investors boosted its stake in Abbott Laboratories by 2.6% during the fourth quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker’s stock worth $7,922,519,000 after buying an additional 1,614,706 shares during the period. J. Stern & Co. LLP boosted its stake in shares of Abbott Laboratories by 12,439.6% during the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock worth $4,926,279,000 after purchasing an additional 39,005,451 shares during the period. Finally, Capital Research Global Investors boosted its position in shares of Abbott Laboratories by 1.0% during the fourth quarter. Capital Research Global Investors now owns 39,169,239 shares of the healthcare product maker’s stock valued at $4,907,523,000 after buying an additional 400,400 shares during the period. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Price Performance

Shares of ABT stock traded down $1.10 during mid-day trading on Tuesday, hitting $101.99. 7,418,005 shares of the stock were exchanged, compared to its average volume of 11,513,019. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $137.49. The firm has a fifty day moving average of $105.75 and a 200 day moving average of $99.66. The company has a market cap of $176.48 billion, a PE ratio of 33.01, a price-to-earnings-growth ratio of 1.89 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. The business had revenue of $12.59 billion during the quarter, compared to analysts’ expectations of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The business’s revenue was up 13.0% compared to the same quarter last year. During the same period in the previous year, the business earned $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Research analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have recently commented on ABT. JPMorgan Chase & Co. upped their price target on shares of Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a report on Friday, July 17th. TD Cowen restated a “buy” rating and set a $135.00 price objective on shares of Abbott Laboratories in a research note on Tuesday, September 8th. The Goldman Sachs Group decreased their target price on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a research report on Wednesday, May 27th. Weiss Ratings upgraded Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, August 6th. Finally, Wells Fargo & Company upped their price target on shares of Abbott Laboratories from $109.00 to $112.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $119.50.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: The agreement resolves the U.S. Department of Justice investigation, related civil claims, and lawsuits brought by certain states and relators. Abbott said the settlement includes no admission of fault or liability, while the government’s criminal investigation has been closed. Abbott Department of Justice settlement announcement
• Positive Sentiment: Abbott stated that government testing of unopened formula from affected infants’ homes was negative for Cronobacter sakazakii, and that no unopened, distributed Abbott formula has ever tested positive for the bacteria. These points may limit some ongoing product-liability concerns. NBC News report on Abbott formula settlement
• Neutral Sentiment: Abbott had recently gained as the broader healthcare sector advanced and after six consecutive losing sessions, suggesting some of the current move reflects market and sector trading rather than company-specific fundamentals alone. Abbott market performance report
• Negative Sentiment: The settlement requires Abbott to pay more than $384 million to resolve allegations that it produced infant formula in potentially contaminated conditions at its Michigan and Arizona facilities, failed to conduct adequate testing, and did not disclose positive contamination tests to regulators. The cash cost and renewed scrutiny of manufacturing controls are weighing on sentiment. Inside Monkey report on Abbott infant-formula legal risks
• Negative Sentiment: The matter relates to the closure of Abbott’s Sturgis, Michigan, facility and the 2022 recall, keeping attention focused on reputational damage, regulatory oversight, and potential disruption in the infant-formula business. RTT News report on Abbott settlement

About Abbott Laboratories

Abbott Laboratories (NYSE: ABT) is a global healthcare company that develops, manufactures and sells medical products and technologies. Its operations span four principal areas: medical devices, diagnostics, established pharmaceutical products and nutrition. Abbott serves healthcare providers, institutions and consumers in markets around the world.

The company’s medical device portfolio includes products for cardiovascular care, diabetes management and other specialties. Its diagnostics business provides laboratory systems, tests and point-of-care solutions, while its nutrition products include infant, child and adult nutritional offerings sold under brands such as Similac, Ensure and Pedialyte.